The Fc protein and glyco-engineered antibodies market is projected to grow at a CAGR of over 30% during 2021-2030, claims Roots Analysis

Published: September 2021

With the emergence of blockbuster drugs, such as Gazyva® (for Chronic Lymphocytic Leukemia) and POTELEGIO® (for Sézary syndrome), Fc engineered antibodies have garnered significant interest in the medical community, for various clinical conditions


Roots Analysis has announced the addition of “Fc Protein and Glyco-engineered Antibodies Market, 2021-2030” report to its list of offerings. 

Over time, a substantial body of evidence has validated the therapeutic applications of Fc engineering platforms; Fc modified antibodies have shown to augment the various immune effector functions, such as antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), antibody-dependent cellular phagocytosis (ADCP) activity and / or the half-life of the molecule

To order this 250+ page report, which features 100+ figures and 110+ tables, please visit

Key Market Insights

The Fc engineered antibodies pipeline features more than 125 marketed drugs / drug development programs
Around 15% Fc protein and glyco-engineered antibodies are marketed, while close to 75% are being evaluated in different phases of clinical trials and 10% in preclinical studies. Examples of marketed Fc engineered antibodies include Gazvya®, Imfinzi®, MONJUVI® and Skyrizi®.  

Around 30 companies claim to be engaged in the development of Fc protein and glyco-engineered antibodies
Around 55% of the aforementioned players are large companies (with more than 5000 employees). It is worth highlighting that, majority of the developers engaged in this domain (54%) are based in North America, followed by Europe (26%) and Asia-Pacific (20%).

Over 1,800 clinical trials are currently evaluating the therapeutic effects of Fc protein and glyco-engineered antibodies, worldwide 
It is worth mentioning that most of the trials were / are being conducted in North America (35%) region;
however, more than 91% of the patients enrolled in trials conducted in North America were enrolled in different sites in the United States. Further, 43% of the trials are being sponsored by non-industry players.
Close to 140 grants have been awarded to support research on Fc protein and glyco-engineered antibodies, since 2019
An estimated USD 63 million in grants have been awarded to various companies / organizations working in this domain, during time period between 2019 and 2021. Almost 50% of the total grant amount was funded by the National Institute of Allergy and Infectious Diseases.

Close to 6,500 patents have been filed / granted for Fc protein and glyco-engineered antibodies, since 2016
Around 30% of these intellectual property documents were filed / granted in the Asia-Pacific; with maximum number of patents filed in Australia. This is followed by North America (32%) and Europe (23%). Leading industry players (in terms of the size of intellectual property portfolio) include Roche, Janssen, Novartis, Genentech, Amgen, MacroGenics and Genmab.

Partnership activity within this domain has grown at a CAGR of 48%, between 2016 and 2020
More than 50% of the total deals have been inked post 2019. Licensing (36%) emerged as the most popular type of partnership model adopted by stakeholders in this domain, followed by clinical trial agreements (16%) and acquisitions / mergers (14%).

The market is anticipated to grow at a CAGR of over 30%, during the period 2021-2030 
Growth in this domain is anticipated to be driven by the drugs that are being developed for the treatment of oncological disorders. North America (primarily the US) and Europe are expected to capture major share of the Fc protein and glyco-engineered antibodies market by 2030, in terms of the sales-based revenues.

To request a sample copy / brochure of this report, please visit this

Key Questions Answered
  • Who are the leading industry and non-industry players engaged in the development of Fc protein and glyco-engineered antibodies?
  • Which are the key disease indications being targeted by Fc engineered antibodies?
  • Which partnership models are commonly adopted by stakeholders engaged in this domain?
  • Which geographies are the most active in conducting clinical trials on Fc protein and glyco-engineered antibodies? 
  • Which are the leading administering institutes supporting the research related to Fc protein and glyco-engineered antibodies? 
  • How has the intellectual property landscape in this market evolved over the years?
  • Which key factors are likely to influence the evolution of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

The financial opportunity within the Fc protein and glyco-engineered antibodies market has been analyzed across the following segments:

  • Type of Fc Engineering
  • Fc Protein Engineering
  • Fc Glyco-engineering
  • Type of Therapy
  • Monotherapy
  • Combination Therapy
  • Therapeutic Area
  • Oncological Disorders
  • Rare Disorders
  • Dermatological Disorders
  • Autoimmune Disorders
  • Infectious Diseases
  • Gastrointestinal Disorders
  • Neurological Disorders
  • Pulmonary Disorders
  • Route of Administration
  • Intravenous
  • Subcutaneous
  • Others
  • Key Geographical Regions 
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World

The research includes profiles of key players (listed below); each profile features an overview of the company, its financial information (if available), brief description of its drug(s), recent developments, and an informed future outlook. 

  • AbbVie
  • Alexion Pharmaceuticals
  • AstraZeneca
  • Genentech
  • MacroGenics
  • Kyowa Kirin

For additional details, please visit
or email

An older edition of our report on this subject is available here

You may also be interested in the following titles: 
1.    TIL-based Therapies Market, 2021-2030
2.    TCR-based Therapies Market, 2021-2030
3.    Peptide Therapeutics Market, 2021-2030

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry